GILEAD SCIENCES Stock Quote

$72.46 arrow  Change: 0.07 %Chge: 0.10% Vol: 277,787
End Of Day Prices
High: 72.46 | Low: 72.13 | Open: 72.13 | Close: 72.46
52 Wk High: 86.18 | 52 Wk Low: 63.78 | Todays Pivot: 72.35
Sector: Healthcare and Pharmaceuticals add stock to watch list

GILD Chart


You need Flash Player to see the chart, please download from the link below

Get Adobe Flash player

Related Healthcare and Pharmaceuticals Companies

United Therapeutics Del 124.16 green arrow 33,437
Quest Diagnostics 83.095 green arrow 45,951
Owens & Minor 28.8 green arrow 47,747
Carefusion 25.67 red arrow 117,963
Varian Med Sys 94.48 red arrow 32,834
Sirona Dental Systems 67.29 red arrow 75,649
United Therapeutics Del 93 green arrow 15,172
Alexion Pharmaceuticals 91.78 red arrow 148,010

Above is a small selection of related companies to Gilead Sciences which compete alongside GILD within the Healthcare and Pharmaceuticals sector. To see more related companies to GILD, view our stock market today information page.

Online News For Gilead Sciences

National Planning Has Cut By $378,210 Its Gilead Sciences (GILD) Position; Proofpoint (PFPT) Sentiment Is 1.32

National Planning Corp decreased Gilead Sciences Inc (GILD) stake by 23.69% reported in 2017Q2 SEC filing. National Planning Corp sold 5,403 shares as Gilead Sciences Inc (GILD)’s stock declined 8.05%. The National Planning Corp holds 17,403 shares with ...


GILD Makes Notable Cross Below Critical Moving Average

GILD's SI was 19.60M shares in November as released by FINRA. Tiker4's total market worth is $919.40M along with 91.03M outstanding shares. GILD institutional ownership is held at 78.1% while insider ownership was 0.2%. The company exchanged hands with ...


Gilead Sciences, Inc. (GILD) Downgraded by Argus to Hold

About 50 shares traded. About shares traded. Novocure Ltd (NASDAQ:NVCR) has declined 0.43% since November 14, 2016 and is downtrending. It has underperformed by 17.22% the S&P500. The company is trading down by 3.28% percent from yesterday's close.


Gilead Sciences Inc (GILD) President and CEO John F Milligan Sold $16 million of Shares

President and CEO of Gilead Sciences Inc ( GILD) John F Milligan sold 220,000 shares of GILD on 11/13/2017 at an average price of $72.88 a share. The total sale was $16 million. Gilead Sciences Inc is a biopharmaceutical company that discovers, develops ...


Paradigm Asset Management Co Has Raised Gilead Sciences (GILD) Holding By $2.12 Billion; Ugi Has 0.98 Sentiment

Paradigm Asset Management Co Llc increased Gilead Sciences Inc. (GILD) stake by 152.59% reported in 2017Q2 SEC filing. Paradigm Asset Management Co Llc acquired 30,000 shares as Gilead Sciences Inc. (GILD)’s stock declined 8.05%. The Paradigm Asset ...



Want To Add This Quote To Your Site?

With our stock widgets you can add a Gilead Sciences quote to your website to keep your users up to date with the market. We have a variety of different styled widgets for GILD to choose from. Visit here to build your stock quote widget »